EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Poirier, V. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poirier, V. L.

Eur J Cardiothorac Surg 1997;11:S39-S44
© 1997 Elsevier Science NL

The heartmate left ventricular assist system: Worldwide clinical results

Victor L. Poirier

Thermo Cardiosystems Inc., 470 Wildwood Street, PO Box 1697, Woburn, MA 01888, USA

To date 482 patients have been treated with TCI's HeartMate® left ventricular assist system (LVAS) at 70 clinical centers worldwide. Of those, 433 patients have undergone treatment with the HeartMate IP (implantable pneumatic) LVAS, while 49 patients were treated with the HeartMate VE (vented electric) LVAS. Currently 65 patients are on the HeartMate LVAS: 51 on the pneumatic version and 14 on the electric version. Of the 482 patients, 64% were transplanted after being supported for an average duration of 72 days (range 1–503 days) to arrive at a cumulative experience of greater than 100 patient years. Neural incidents occurred in 19% of the patients as a result of a variety of complications, including but not limited to air emboli, seizures, drug reactions, as well as thromboembolic complications whether device-related or not. Device-related complications remain quite low at the 2–3% range with minimal or no anticoagulant therapy. Fourteen patients on the electric version have been discharged to live at home for periods ranging from 1 to 7 months. Patients while being supported have successfully gone back to work or to school.




This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
A. El-Banayosy, R. Korfer, L. Arusoglu, L. Kizner, M. Morshuis, H. Milting, G. Tenderich, O. Fey, and K. Minami
Device and patient management in a bridge-to-transplant setting
Ann. Thorac. Surg., March 1, 2001; 71 (2007): S98 - S102.
[Abstract] [Full Text] [PDF]


Home page
PerfusionHome page
A K Mahmood, J M Courtney, S Westaby, M Akdis, and H Reul
Critical review of current left ventricular assist devices
Perfusion, September 1, 2000; 15(5): 399 - 420.
[PDF]


Home page
PerfusionHome page
A El-Banayosy, L Arusoglu, L Kizner, O Fey, K Minami, and R Korfer
Complications of circulatory assist
Perfusion, July 1, 2000; 15(4): 327 - 331.
[PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1997 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.